 BridgeBio Pharma Inc NASDAQ: BBIO and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry fosdenopterin Injection to reduce the risk of mortality in patients with molybdenum cofactor deficiency MoCD Type-A. MoCD is a rare metabolic disorder characterized by severe and rapidly progressive neurologic damage caused by the functional loss of sulfite oxidase, 1 of 4 molybdenum-dependent enzymes. 